



Updated June 2012

Prasugrel (Efient®▼) for patients suffering from Acute Coronary Syndrome and undergoing PCI.

The New Therapies Subgroup again discussed the above drug at a meeting on 21st June 2011. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Prasugrel for patients suffering from ACS and following PCI.

The group does not recommend the use of Prasugrel (Efient®) over other antiplatelet therapies (i.e. Clopidogrel and Ticagrelor) for the above indication.

It was agreed at a Joint GMCCSN and GMMMG meeting that where appropriate Ticagrelor should be recommended over prasugrel as per the joint protocols (see [here](#)). Prasugrel may be a suitable option in those patients who are unable to take ticagrelor or clopidogrel.

According to set criteria Prasugrel was deemed to be a low priority for funding.

Review date: June 2015

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.